This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent results from the phase 3 innovaTV 301 global trial, studying Genmab and Seagen's TIVDAK in recurrent or metastatic cervical cancer.

Ticker(s): SGEN, GMAB

Who's the expert?

Institution: University of Toronto

  • Professor and Chair of the division of Gynecologic Oncology at the University of Toronto, and Sunnybrook Health Sciences Center. 
  • Currently manages 200 patients with ovarian cancer.
  • Interests and expertise include clinical trials, germ cell tumours, Gestational Trophoblastic Disease, Cervical Cancer (innovative surgical approaches, sentinel lymph nodes, and fertility sparing approaches), and Radical and Reconstructive Surgical Techniques in Gynecologic Oncology. 
  • Author of over 200 peer reviewed publications; Member of MAGIC a multidisciplinary multicooperative group team developing protocols in Malignant Germ Cell Tumours, and previous co-chair of the cervical cancer task force for the NCI (US). 

Interview Questions

Describe your background and practice setting

Added By: ben_admin

How many patients with metastatic cervical cancer do you manage?

Added By: ben_admin

What are your thoughts on the phase 3 InnovaTV 301 trial?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.